Mayo Clinic Laboratory and pathology research roundup: August 15
Share this:
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Featured Abstract
Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis.
Whether TMPRSS2-ERG fusion and TP53 gene alteration coordinately promote prostate cancer (PCa) remains unclear. Here we demonstrate that TMPRSS2-ERG fusion and TP53 mutation / deletion co-occur in PCa patient specimens and this co-occurrence accelerates prostatic oncogenesis. p53 gain-of-function (GOF) mutants are now shown to bind to a unique DNA sequence in the CTNNB1 gene promoter and transactivate its expression.
Published to PubMed This Week
- The evolving role of cardiac troponin: From acute to chronic coronary syndromes.
Journal of the American College of Cardiology - Gynecologic-type adenocarcinoma with mixed serous and endometrioid features in a male patient.
Mayo Clinic Proceedings - Benign enhancing foramen magnum lesions.
AJNR American Journal of Neuroradiology - Candida guilliermondii/Kodamaea ohmeri endocarditis.
Mycopathologia - Association of adverse effects with high serum posaconazole concentrations.
Medical Mycology - Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML).
Leukemia - Relationship among three common hematological premalignant conditions.
Leukemia - Two tumors with combined features of bronchiolar adenoma/ciliated muconodular papillary tumor and sclerosing pneumocytoma.
American Journal of Clinical Pathology - Update on endoscopic dysplasia surveillance in IBD.
American Journal of Gastroenterology - A lncRNA from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling.
Molecular Cell
